Skip to main content

Table 3 Steady-state plasma pharmacokinetics of SBECD and voriconazole during CVVH

From: Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

SBECD        
  Cmax (mg/L) Cmin (mg/L) T1/2 (hrs) AUC0-12 (mg*hr/L) Cls(L/hr/kg) Vd (L/kg) CVVH CL (L/hr/kg)
Mean 687.0 214.5 6.3 4396 0.03 0.3 0.02
SD 500.4 202.6 1.6 3325 0.02 0.2 0.01
Median 561.1 165.2 6.2 3621 0.02 0.2 0.01
25% 216.2 38.7 5.3 1352 0.01 0.1 0.01
75% 1102.4 305.8 7.3 6804 0.05 0.4 0.02
Voriconazole        
  Cmax (mg/L) Cmin (mg/L) T1/2 (hrs) AUC0-12 (mg*hr/L) Cls(L/hr/kg) Vd (L/kg) CVVH CL (L/hr/kg)
Mean 4.1 2.4 19.5 37 0.13 3.2 0.02
SD 1.4 1.1 10.7 14 0.06 1.5 0.02
Median 4.1 2.3 19.0 38 0.12 2.7 0.02
25% 3.3 2.0 13.1 30 0.09 2.1 0.01
75% 5.1 3.0 22.5 41 0.14 3.7 0.02
  1. SBECD, sulfobutylether-β-cyclodextrin; CVVH, continuous venovenous hemofiltration; Cmax, maximum drug concentration in the plasma; Cmin, minimum drug concentration in the plasma; T1/2, half-life; AUC0-12 area under the concentration-time curve from time 0 to 12 hours; Cls, total systemic clearance; Vd, volume of distribution; CVVH CL clearance by continuous venovenous hemofiltration; SD, standard deviation.